Skip to main content
American Transplant Congress, Seattle | 18–22 May 2013
22, Oct 2013

American Transplant Congress, Seattle-scientific exchange between the various disciplines...

The American Transplant Congress was held between May 18-22 in Seattle this year. The American Transplant Congress is the premier venue for scientific exchange between the various disciplines uniquely involved in solid organ transplantation.

Plexision’s exhibit profiled its rejection-risk test, Pleximmune, and upcoming assays aimed at measuring anti-viral immunity at this conference.

Visitors expressed a strong interest in determining whether renal allograft dysfunction could be attributed to loss of anti-viral immunity in patients demonstrating BK viruria. Plexision's upcoming tests should address this need within the next three months.

Another need among adult liver transplant recipients is distinguishing exacerbations of hepatitis C from acute cellular rejection. This particular problem is not always resolved by liver transplant biopsies. Clinicians acknowledged that measuring an exuberant donor-specific alloresponse, which is known to cause rejection, could be a valuable adjunct in formulating immunosuppression strategies for such patients.

Plexision develops cellular biomarkers for personalized diagnostics and drug development in organ transplantation and immunological disorders.


Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.